Your browser doesn't support javascript.
loading
Hypomethylating agents (HMAs) show benefit in AML rather than in intermediate/high-risk MDS based on genetic mutations in epigenetic modification (EMMs): from a retrospective study.
Wang, Ruiqi; Xu, Yuanyuan; Wang, Bianhong; Wang, Hong; Wang, Mengzhen; Jing, Yu; Gao, Xiaoning; Yu, Li.
Affiliation
  • Wang R; Medicine School, Nankai University, 94 Weijin Road, Tianjin, 300071, China.
  • Xu Y; Department of Hematology, Chinese PLA General Hospital, Medical School of Chinese PLA, 28 Fuxing Road, Beijing, 100853, China.
  • Wang B; Department of Hematology-Oncology, Carson International Cancer Center, Shenzhen University General Hospital, Shenzhen University Health Science Center, 1098 Xueyuan Avenue, Shenzhen, 518060, China.
  • Wang H; Department of Hematology, Chinese PLA General Hospital, Medical School of Chinese PLA, 28 Fuxing Road, Beijing, 100853, China.
  • Wang M; Medicine School, Nankai University, 94 Weijin Road, Tianjin, 300071, China.
  • Jing Y; Department of Hematology, Chinese PLA General Hospital, Medical School of Chinese PLA, 28 Fuxing Road, Beijing, 100853, China.
  • Gao X; Medicine School, Nankai University, 94 Weijin Road, Tianjin, 300071, China.
  • Yu L; Department of Hematology, Chinese PLA General Hospital, Medical School of Chinese PLA, 28 Fuxing Road, Beijing, 100853, China.
Ann Hematol ; 103(1): 61-71, 2024 Jan.
Article in En | MEDLINE | ID: mdl-37926751
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Myelodysplastic Syndromes / Leukemia, Myeloid, Acute Limits: Aged / Humans Language: En Year: 2024 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Myelodysplastic Syndromes / Leukemia, Myeloid, Acute Limits: Aged / Humans Language: En Year: 2024 Type: Article